// App-Quantinova.ai

2113 : Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Researchers

Presenter

  • Luke Coyle

Principal Investigators

  • Nicholas J. Morley

  • Alessandro Rambaldi

  • Kylie D. Mason

  • Gregor Verhoef

  • Caroline Furness

  • Rajendra Desai

  • Noemi Mergen

Medical Centers

  • Royal North Shore Hospital, Sydney, Australia

  • Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom

  • Department of Oncology and Hematology University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

  • Department of Medicine, University of Melbourne, Melbourne, Australia

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Department of Paediatric Haemato-Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom

  • Biostatistical Science, IQVIA Inc, Mumbai, India

  • Amgen Research (Munich), Munich, Germany

Locations

  • Australia

  • United Kingdom

  • Italy

  • Belgium

  • India

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • B-Cell Non-Hodgkin Lymphoma

Biomarkers

  • Myelin proteolipid protein

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • NCT02910063

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved